Sanara MedTech Inc. acquires Scendia Biologics, LLC for USD 7,360,000 (2022)

Deal facts

Buyer: Sanara MedTech Inc.
Target: Scendia Biologics, LLC
Deal value: USD 7,360,000
Announced: 5 July 2022
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash, shares, earn-out

Sources

SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

1 Jul 2022CompletedClosed
Sanara MedTech Inc. completes acquisition of Scendia Biologics, LLC
Item 1.01 Entry into a Material Definitive Agreement. On July 1, 2022, Sanara MedTech Inc., a Texas corporation (the “Company”), entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) by and among the Company, Scendia Biologics, LLC, a Delaware limited liability company (“Scendia”), and Ryan Phillips (the “Seller”) pursuant to which, and in accordance with the terms and c
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Scendia Biologics by Sanara MedTech, a deal that closed in July 2022 for a total value of seven point three six million US dollars. This transaction sits firmly within the healthcare sector and represents a classic strategic move where a buyer seeks to integrate specific biological capabilities rather than simply buying a revenue stream. The structure is instructive for any SME founder watching the market, as it combines cash, shares, and an earn-out. This mix tells us the buyer wanted immediate control but remained cautious about the future performance of the target, a dynamic that often arises when the asset is high-potential but unproven at scale.

The inclusion of an earn-out is not merely a negotiation tactic; it is a risk allocation mechanism. By deferring part of the consideration until future milestones are met, Sanara MedTech protected itself against overpaying for technology that might not integrate smoothly or generate the expected returns. For the founder of Scendia, this structure likely meant accepting a lower upfront price in exchange for the chance to capture the full value if the business met its targets. In the US healthcare landscape, where regulatory pathways can be complex and product adoption slow, this approach is common. It shifts the burden of execution risk onto the original management team, ensuring they remain motivated post-closing to deliver the promised results.

We believe this deal highlights a critical reality for founders in the life sciences space: the headline price is rarely the whole story. The split between cash, equity, and contingent payments defines the actual risk profile of the exit. A deal valued at seven million dollars on paper could be worth significantly less if the earn-out conditions are too aggressive or if the share component underperforms. The SME founder must scrutinise the specific triggers for the deferred payment. Are they based on revenue, EBITDA, or regulatory approval? Without clarity on these mechanics, the final payout remains uncertain, regardless of the initial agreement.

Your immediate action this week should be to map out the specific performance milestones in any draft term sheet you hold. Do not accept vague language regarding the earn-out. Define the exact metrics, the measurement period, and the formula for calculation before you sign. If the buyer cannot agree to clear, objective targets, you must assume the deferred portion of the deal will not materialise and price your business accordingly today.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2022 deals More strategic acquisition deals More from Sanara MedTech Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history